Kiniksa Pharmaceuticals Insider Sells $309K Worth of Shares Amid Stock Surge
The chief accounting officer of Kiniksa Pharmaceuticals sold 6,625 shares for approximately $309,000 on April 9, 2026. The transaction was conducted under a pre-arranged 10b5-1 trading plan and did not involve derivative securities or indirect holdings. The insider still holds 27,418 Class A ordinary shares post-transaction.
Tickers: $KNSA
Topics: executive transactions insider trading SEC Form 4 stock ownership